Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
Survodutide is a dual GLP-1 / glucagon receptor agonist. The GLP-1 arm drives appetite suppression and glycemic control while the glucagon arm raises energy expenditure and hepatic fat oxidation. It works through satiety and metabolic-rate pathways, not anabolic ones, and does not affect testosterone or muscle building directly. The Phase 3 SYNCHRONIZE-1 obesity trial (Le Roux et al., NEJM 2026) reported -12.2% (3.6mg) to -13.0% (6.0mg) mean weight loss at 76 weeks vs -5.4% for placebo, similar magnitude to semaglutide. Rated 3.5: slightly above the pure GLP-1s (3) because the glucagon arm makes it metabolically more aggressive, but below the triple agonist retatrutide (4), which produced roughly double the weight loss in its own Phase 2 trial.
Overview
A dual GLP-1 / glucagon receptor agonist from Boehringer Ingelheim in Phase 3 development for obesity and metabolic dysfunction-associated steatohepatitis (MASH). By adding glucagon-receptor activity to GLP-1, it pairs appetite suppression with increased energy expenditure and hepatic fat burning, which makes it particularly interesting for fatty liver disease. The SYNCHRONIZE-1 Phase 3 obesity trial (NEJM 2026) reported -12.2% (3.6mg dose) to -13.0% (6.0mg dose) mean weight loss at 76 weeks vs -5.4% on placebo, with roughly 72% of treated participants losing at least 5% of body weight vs 46% on placebo.
Important Warnings
- •GLP-1-class agents are contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2)
- •The glucagon component can increase heart rate and, in principle, blood glucose. Monitor, especially in diabetics
- •Rapid weight loss causes lean-mass (muscle) loss unless protein and resistance training are prioritized
- •Rebound weight gain is common after discontinuation without sustained lifestyle change
- •Do not stack with other GLP-1/GIP/glucagon agonists, additive GI, dehydration and muscle-loss risk
- •Investigational: long-term safety data is still being generated in Phase 3
Purpose & Use Cases
Weight Loss
SYNCHRONIZE-1 Phase 3 reported -12.2% (3.6mg) to -13.0% (6.0mg) mean weight loss at 76 weeks vs -5.4% on placebo, with 71.9-72.6% of treated participants losing at least 5% of body weight vs 46.3% on placebo.
MASH / Liver Fat Reduction
The glucagon component drives hepatic fat oxidation. The Phase 2 NEJM trial showed MASH improvement without worsening fibrosis in up to 62% of treated participants (vs 14% placebo), and the SYNCHRONIZE-MASLD Phase 3 trial showed a ≥30% reduction in liver fat in 84.2% of treated participants vs 24.3% on placebo, a differentiator from pure GLP-1 agents.
Metabolic Health
Improves glycemic markers, blood pressure and lipids alongside weight loss, with added energy-expenditure effects from glucagon activity.
Benefits
- Strong Phase 3 weight loss (-12.2% to -13.0% at 76 weeks, SYNCHRONIZE-1)
- Dual mechanism adds energy expenditure and hepatic fat burning on top of appetite suppression
- Leading candidate for MASH / fatty liver disease
- Once-weekly subcutaneous dosing
- Broad metabolic improvements (glucose, blood pressure, lipids)
Good to Know
The glucagon arm is the differentiator
Adding glucagon-receptor activity to GLP-1 raises energy expenditure and burns hepatic fat, which is why survodutide is a front-runner for MASH (fatty liver). It also means a bit more heart-rate rise and glucose complexity than a pure GLP-1.
Liver disease is a primary target, not just weight
Beyond obesity (SYNCHRONIZE), survodutide is in a dedicated Phase 3 MASH cirrhosis outcomes trial (LIVERAGE-Cirrhosis, currently recruiting) after Phase 2 NEJM data showed MASH improvement without worsening fibrosis in up to 62% of participants. That therapeutic angle distinguishes it from appetite-only agents.
Lean-mass loss during rapid weight loss
As with all satiety agents, weight lost can include significant muscle if intake and training lapse. High protein plus resistance training is what protects lean tissue, critical in a physique context.
No anabolic or hormonal action
Does not raise or suppress testosterone, does not aromatize, no HPTA effect. No AI and no PCT considerations apply: it is a metabolic tool.
Rebound weight is expected
Appetite and energy balance normalize after stopping. Weight regain is the default without established diet and training habits.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 0.6 – 2.4 mg/week |
| Intermediate | 2.4 – 3.6 mg/week |
| Advanced | 3.6 – 6 mg/week |
No survodutide trial has tested a dose above 6.0mg/week, that is the highest maintenance dose used across the Phase 2 obesity dose-finding trial (0.6/2.4/3.6/4.8mg targets), the Phase 2 MASH trial (2.4/4.8/6.0mg targets) and the Phase 3 program (SYNCHRONIZE-1 obesity: 3.6mg or 6.0mg targets; SYNCHRONIZE-MASLD: 6.0mg). Titration is gradual, SYNCHRONIZE-1 escalates over roughly 20 weeks with optional re-escalation attempts if GI symptoms occur, specifically to blunt nausea/vomiting and the glucagon-driven heart-rate rise. Start low and go slow.
Long half-life supports once-weekly subcutaneous dosing.
Side Effects
Nausea
very commonThe dominant side effect during titration, from GLP-1-driven delayed gastric emptying. Reported in ~66% of participants vs ~23% on placebo in the Phase 2 MASH trial (NEJM 2024).
Very slow titration; smaller meals; avoid fatty foods.
Vomiting
very commonReported in ~41% of participants vs ~4% on placebo in the Phase 2 MASH trial (NEJM 2024). More likely with faster dose increases or overeating.
Slow titration; stop eating when satisfied.
Diarrhea
very commonReported in ~49% of participants vs ~23% on placebo in the Phase 2 MASH trial (NEJM 2024), usually during dose escalation.
Stay hydrated; slow titration.
Increased Heart Rate
commonGlucagon-receptor activation can raise heart rate, typically by a modest amount but more than pure GLP-1 agents.
Monitor heart rate; slow titration usually keeps it manageable.
Constipation
uncommonSlowed GI motility can cause constipation.
Fiber, hydration, movement.
Decreased Appetite
very commonExpected effect; can be excessive and lead to under-eating protein.
Prioritize protein; do not skip meals entirely.
General Mitigation Strategies
GI side effects are dose-dependent and ease with a slow, patient titration. Monitor heart rate given the glucagon component. Keep protein high and train with resistance to protect lean mass during rapid loss. Stay well hydrated to reduce dehydration-related kidney risk. Discontinue and seek care for severe persistent abdominal pain (pancreatitis concern).
Support Supplements
Ancillary supplements commonly run alongside Survodutide to manage side effects, support the target tissue, or fill nutrient demands it creates.
High Protein Intake
KeyStrong appetite suppression makes under-eating protein easy, which accelerates lean-mass loss. Adequate protein is the primary lever to preserve muscle during weight loss.
- Dose
- 1.6-2.2 g per kg bodyweight per day
- Timing
- Spread across meals; eat protein first when appetite is low
Resistance Training
KeyThe essential stimulus for retaining lean mass in a caloric deficit. Without it, a larger share of lost weight is muscle. The key companion protocol, not a supplement.
- Timing
- 2-4 sessions per week, progressive overload
Creatine Monohydrate
Supports strength and lean-mass retention during a deficit; well-evidenced and inexpensive.
- Dose
- 3-5 g daily
- Timing
- Any time, daily and consistent
Electrolytes & Hydration
GI losses and reduced intake can cause dehydration and electrolyte depletion; supports the glucagon-related heart-rate response and kidney protection.
- Dose
- Sodium/potassium/magnesium to appetite; deliberate fluid intake
- Timing
- Daily, more around GI episodes
Post Cycle Therapy (PCT)
Not anabolic-hormonal. Does not affect the HPTA. No PCT required. Maintain diet and training habits to limit weight regain after stopping.
How It Works
Survodutide is an acylated peptide that co-activates the GLP-1 receptor and the glucagon receptor. GLP-1 agonism suppresses appetite, slows gastric emptying, stimulates glucose-dependent insulin secretion and improves glycemic control. Glucagon-receptor agonism increases resting energy expenditure, promotes hepatic lipid oxidation and thermogenesis, and helps mobilize liver fat, the basis for its MASH program. The glucagon arm can also modestly raise heart rate and, in principle, blood glucose, which is offset by the GLP-1 arm. Fatty-acid acylation extends its half-life to support once-weekly injection.
Fundamentals
Reference on the practices relevant to Survodutide: how they are done and where they go wrong. Not a recommendation to use it.
Legal Status
Investigational. Phase 3 program from Boehringer Ingelheim: SYNCHRONIZE-1 (obesity, primary results published NEJM June 2026) and SYNCHRONIZE-2 (obesity with type 2 diabetes) are complete; SYNCHRONIZE-MASLD (obesity + liver fat, Nature Medicine June 2026) is published; LIVERAGE-Cirrhosis (MASH cirrhosis outcomes) and a cardiovascular outcomes trial are still recruiting/ongoing. Not yet FDA-approved.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Survodutide is not explicitly listed on the WADA Prohibited List, and approved GLP-1-class weight agents (semaglutide, tirzepatide) are not banned. However, as a non-FDA-approved investigational compound, survodutide could fall under S0 (Non-Approved Substances) for tested athletes, which prohibits any pharmacological substance with no current approval by a governmental regulatory health authority for human therapeutic use. Verify with your sport's anti-doping authority before competition.
References
- le Roux et al.: Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1 Phase 3, NEJM 2026)
- Sanyal et al.: Phase 2 Trial of Survodutide in MASH and Fibrosis - NEJM
- Kaplan et al.: Survodutide in Obesity and MASLD (SYNCHRONIZE-MASLD Phase 3) - Nature Medicine
- le Roux et al., Glucagon/GLP-1 dual agonist survodutide for obesity: Phase 2 dose-finding trial - Lancet Diabetes & Endocrinology
- LIVERAGE-Cirrhosis Phase 3 trial record - ClinicalTrials.gov (NCT06632457)